H.C. Wainwright analyst Ed Arce downgraded Axcella Health to Neutral from Buy without a price target. The company announced a strategic repositioning and restructuring plan to focus solely on its long COVID program, and as a result is discontinuing its ongoing Phase 2b trial of AXA1125 in nonalcoholic steatohepatitis, Arce tells investors in a research note. The analyst regards the discontinuation of the AXA1125 program to be a "major detriment" to the valuation of Axcella shares. He also sees a limited number of options for Axcella to successfully finance a planned Phase 2b long COVID study due to a lack of near-term catalysts. Axcella Health shares are down 25% to 67c in midday trading.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AXLA:
- Axcella announces corporate restructuring, will reduce workforce by 85%
- This Insider Bought Axcella Health (NASDAQ:AXLA) Stock Worth $6M
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue